Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 11.22 is 29% above its 5-year average of 8.73, around the middle of its 5-year range (0.79–24.75).
As of the fiscal period ended Tuesday, June 30, 2026. 8.06% below its 12-month average of 12.20.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.22.
CURRENT RATIO
11.22
CURRENT RATIO AVG TTM
12.20
CURRENT RATIO AVG 3Y
13.07
CURRENT RATIO AVG 5Y
8.73
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-8.06%
CURRENT VS 3Y AVG
-14.12%
CURRENT VS 5Y AVG
+28.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+199.21%
vs the sector median at left
Satellos Bioscience Inc.
Market Cap
$10.40M
Current Ratio
11.22
TTM Avg
12.20
3Y Avg
13.07
5Y Avg
8.73
Market Cap
$10.23M
Current Ratio
1.87
TTM Avg
6.94
3Y Avg
8.04
5Y Avg
8.76
Market Cap
$10.46M
Current Ratio
2.64
TTM Avg
7.53
3Y Avg
7.44
5Y Avg
5.23
Market Cap
$10.65M
Current Ratio
3.69
TTM Avg
5.96
3Y Avg
7.84
5Y Avg
10.45
Market Cap
$10.10M
Current Ratio
1.57
TTM Avg
1.67
3Y Avg
1.44
5Y Avg
1.16
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.40M | 11.22 | 12.20 | 13.07 | 8.73 |
| Polyrizon Ltd. (PLRZ)vs › | $10.80M | 36.37 | 19.59 | 9.84 | 7.09 |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.23M | 1.87 | 6.94 | 8.04 | 8.76 |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.46M | 2.64 | 7.53 | 7.44 | 5.23 |
| Senti Biosciences, Inc. (SNTI)vs › | $10.01M | 0.83 | 3.08 | 4.37 | 4.67 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | 3.69 | 5.96 | 7.84 | 10.45 |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.10M | 1.57 | 1.67 | 1.44 | 1.16 |
| Lifeward Ltd. (LFWD)vs › | $10.10M | 2.33 | 1.70 | 5.47 | 8.37 |
| MetaVia Inc. (MTVA)vs › | $9.82M | 2.06 | 1.94 | 2.63 | 3.51 |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.92M | 5.63 | 4.29 | 4.04 | 3.65 |
Current Ratio
11.22
Quick Ratio
11.22
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 11.22 |
| 2026-03-31 | 16.48 |
| 2025-12-31 | 7.77 |
| 2025-09-30 | 10.70 |
| 2025-06-30 | 14.84 |
| 2025-03-31 | 16.44 |
| 2024-12-31 | 14.16 |
| 2024-09-30 | 6.68 |
| 2024-06-30 | 7.25 |
| 2024-03-31 | 9.13 |
| 2023-12-31 | 11.13 |
| 2023-09-30 | 19.29 |
| 2023-06-30 | 24.75 |
| 2023-03-31 | 1.00 |
| 2022-12-31 | 0.79 |
| 2022-09-30 | 1.69 |
| 2022-06-30 | 1.04 |
| 2022-03-31 | 2.14 |
| 2021-12-31 | 2.59 |
| 2021-09-30 | 3.29 |
| 2021-06-30 | 0.98 |
| 2021-03-31 | 1.14 |
| 2020-12-31 | 5.13 |
| 2020-09-30 | 0.58 |
| 2020-06-30 | 0.75 |
| 2020-03-31 | 1.03 |
| 2019-12-31 | 1.81 |
| 2019-09-30 | 4.37 |
| 2019-06-30 | 0.61 |
| 2019-03-31 | 1.17 |
| 2018-12-31 | 0.22 |
| 2018-09-30 | 0.39 |
| 2018-06-30 | 1.06 |
| 2018-03-31 | 4.21 |
| 2017-12-31 | 4.77 |
